- Home
- TXMD vs NCEL Comparison
TXMD vs NCEL Comparison
Compare TXMD & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXMD | NCEL |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 4 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 20.6M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | TXMD | NCEL |
|---|---|---|
| Price | $2.02 | $3.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.3K | ★ 31.5K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,761,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $212.00 | ★ N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $0.98 | $1.83 |
| 52 Week High | $2.95 | $5.12 |
Technical Indicators
Market Signals| Indicator | TXMD | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 52.22 |
| Support Level | $2.10 | $3.03 |
| Resistance Level | $2.29 | $3.54 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 80.83 | 55.71 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.